The clean, comprehensive Phase 3 win across all endpoints de-risks bitopertin substantially. Watch for the NDA resubmission by end of 2026 and FDA acceptance; the mid-2027 PDUFA date is the next major catalyst. The stock may gap up significantly on this data.
Price Chart
Executive Summary
Disc Medicine announced overwhelmingly positive topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), meeting all co-primary and secondary endpoints with high statistical significance. The company plans to resubmit an NDA to the FDA by end of 2026 with a decision anticipated by mid-2027, positioning bitopertin as a potential first-in-class disease-modifying therapy for EPP.
Key Facts
- APOLLO Phase 3 trial met co-primary endpoints: PPIX reduction (-41.4% vs placebo, p<0.0001) and increased monthly total time in light without pain (+12.2 hours vs placebo, p=0.0010)
- All secondary endpoints met with statistical significance, including reduction in phototoxic reactions (p<0.0001)
- Quality-of-life exploratory endpoints (PGIC, PGIS) also statistically significant (p<0.0001)
- Bitopertin well-tolerated; most common TEAE was mild/moderate transient dizziness (50%), no Grade 3+ events
- Disc plans to resubmit NDA to FDA by end of 2026, with FDA decision anticipated by mid-2027
- Trial enrolled 183 patients across US, Canada, Europe, and Australia
Financial Impact
Positive Phase 3 data for a first-in-class therapy in EPP, a rare disease with no cure and only one approved therapy (Scenesse). Approval would open a significant commercial opportunity; early-stage biotech with primary asset success typically drives 8-15% CAR on approval events.
Risk Factors
- FDA could issue a CRL on CMC or other non-clinical grounds despite strong efficacy data
- Competition from Scenesse (afamelanotide) and any future entrants
- Commercial adoption risk if pricing/reimbursement is unfavorable in a small patient population
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383263 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13D/A | $77.66 | awaiting T+20 | awaiting T+20 | $79.90 (+2.88%) |
Oct 22, 2026 5d ago | 8-K | $74.51 | awaiting T+20 | awaiting T+20 | $79.90 (−7.23%) |
Oct 21, 2026 6d ago | 424B5 | $75.03 | awaiting T+20 | awaiting T+20 | $79.90 (−6.49%) |
Oct 21, 2026 6d ago | 144 | $75.03 | awaiting T+20 | awaiting T+20 | $79.90 (+6.49%) |
Oct 21, 2026 6d ago | 144 | $75.03 | awaiting T+20 | awaiting T+20 | $79.90 (+6.49%) |
Oct 21, 2026 6d ago | 144 | $75.03 | awaiting T+20 | awaiting T+20 | $79.90 (+6.49%) |
Oct 20, 2026 7d ago | 144 | $76.00 | awaiting T+20 | awaiting T+20 | $79.90 (+5.13%) |
Oct 20, 2026 7d ago | 144 | $76.00 | awaiting T+20 | awaiting T+20 | $79.90 (+5.13%) |
Oct 20, 2026 7d ago | 144 | $76.00 | awaiting T+20 | awaiting T+20 | $79.90 (+5.13%) |
Oct 19, 2026 8d ago | 424B5 | $79.48 | awaiting T+20 | awaiting T+20 | $79.90 (−0.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers